Ra Pharmaceuticals Inc (RARX) Expected to Announce Earnings of -$0.72 Per Share
Analysts expect that Ra Pharmaceuticals Inc (NASDAQ:RARX) will post ($0.72) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have provided estimates for Ra Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.73) and the highest is ($0.71). Ra Pharmaceuticals posted earnings of ($0.73) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 1.4%. The business is expected to report its next earnings report on Monday, March 5th.
On average, analysts expect that Ra Pharmaceuticals will report full-year earnings of ($2.46) per share for the current financial year, with EPS estimates ranging from ($2.47) to ($2.45). For the next financial year, analysts forecast that the business will post earnings of ($3.25) per share, with EPS estimates ranging from ($3.78) to ($2.72). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Ra Pharmaceuticals.
Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.06).
Several hedge funds and other institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its stake in shares of Ra Pharmaceuticals by 30.6% in the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock worth $204,000 after acquiring an additional 2,543 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Ra Pharmaceuticals by 26.1% in the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock worth $390,000 after acquiring an additional 4,300 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Ra Pharmaceuticals by 7.0% in the second quarter. Goldman Sachs Group Inc. now owns 73,103 shares of the company’s stock worth $1,370,000 after acquiring an additional 4,751 shares during the last quarter. New York State Common Retirement Fund increased its stake in shares of Ra Pharmaceuticals by 87.8% in the second quarter. New York State Common Retirement Fund now owns 13,900 shares of the company’s stock worth $260,000 after acquiring an additional 6,499 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Ra Pharmaceuticals by 70.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 21,800 shares of the company’s stock worth $409,000 after acquiring an additional 9,000 shares during the last quarter. 69.64% of the stock is currently owned by institutional investors and hedge funds.
Ra Pharmaceuticals (RARX) traded down $0.18 during trading hours on Wednesday, hitting $8.00. The company had a trading volume of 122,573 shares, compared to its average volume of 116,349. Ra Pharmaceuticals has a fifty-two week low of $7.15 and a fifty-two week high of $27.84. The firm has a market capitalization of $185.09, a PE ratio of -3.24 and a beta of 6.29.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2018/01/20/ra-pharmaceuticals-inc-rarx-expected-to-announce-earnings-of-0-72-per-share.html.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.